Edith M. Lord

University of Rochester Medical Center — United States

Medicine · Health Sciences

45h-index7.3kcitations233works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(76), Immunotherapy and Immune Responses(60), Immune Cell Function and Interaction(29), Cancer, Hypoxia, and Metabolism(26), Cancer Cells and Metastasis(22)

Publications232 total

Type I Interferons: Unraveling their Role in the Response to Short Course Radiotherapy in Rectal Cancer 3621
The Journal of Immunology·2025Open Access
Improving Stereotactic Body Radiation Therapy by Rewiring Immunosuppressive Neutrophils in Murine Pancreatic Ductal Adenocarcinoma
International Journal of Radiation Oncology*Biology*Physics·2025
In situ VIS-NIRS probe measurements for pH management
2025Open Access
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Local delivery of SBRT and IL-12 to Murine PDAC Tumors Modulates Hematopoiesis
2025
Improving SBRT by re-wiring immunosuppressive neutrophils in murine pancreatic ductal adenocarcinoma
2025Open Access
Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models
Cancers·2025· 3 citedOpen Access
Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer
Molecular Therapy — Nucleic Acids·2024· 10 citedOpen Access
Local Delivery of SBRT and IL12 by mRNA Technology Overcomes Immunosuppressive Barriers to Eliminate Pancreatic Cancer
2023· 3 citedOpen Access
New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy
Cell Death and Disease·2023· 10 citedOpen Access
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
Journal for ImmunoTherapy of Cancer·2023· 25 citedOpen Access
New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy
Research Square (Research Square)·2023Open Access
Data from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S4 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S2 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S5 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S5 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S6 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S1 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
Figure S4 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
2023Open Access
page 1 of 12Next →

Frequent Co-authors

John G. Frelinger(16), Scott A. Gerber(9), Sydney M. Evans(9), C. J. Koch(8), Cameron J. Koch(6), Scott A. Gerber(5), W. Timothy Jenkins(5), Bruce M. Fenton(5), James P. Moran(4), Abigail L. Sedlacek(4), Brian A. Belt(4), David C. Linehan(4), Amit A. Lugade(3), Elizabeth W. Sorensen(3), Robert A. Bambara(3), Bradley N. Mills(3), Joseph D. Murphy(3), Booyeon J. Han(3), Ankit Patel(3), Jung‐Eun Lee(3)